CA
ZBH icon

Claris Advisors’s Zimmer Biomet ZBH Stock Holding History

Claris Advisors’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21
Closed -$2.27K – 1201
2024
Q3 		$2.27K Buy
+21
New +$2.29K ﹤0.01% 325

Other funds holding ZBH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Claris Advisors's ZBH Position: Q4 2024 in Review

Claris Advisors sold out of Zimmer Biomet (ZBH) in Q4 2024, closing a stake of 21 shares — an estimated $2.27K sold.

Claris Advisors first reported a position in ZBH in Q3 2024 and held it in 1 quarter. The position peaked at $2.27K in Q3 2024. 1,027 funds tracked by Wall St. Rank hold ZBH as of Q4 2024.

  • Claris Advisors reported no remaining Zimmer Biomet position as of Q4 2024 after selling out during the quarter.
  • Claris Advisors sold 21 Zimmer Biomet shares in Q4 2024, an estimated $2.27K.
  • Claris Advisors first reported a position in Zimmer Biomet in Q3 2024 and held it in 1 quarter.
  • Claris Advisors's Zimmer Biomet position peaked at $2.27K in Q3 2024.
  • 1,027 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.